Literature DB >> 6494764

Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia.

M Cucuianu, T Fekete, C Marcusiu, R Mösler, A Duţu.   

Abstract

The variations of dilute blood clot lysis time (DBCLT) in 103 diabetic patients were investigated in terms of insulin dependency, body weight, serum lipids and presence of diabetic vascular diseases. The results showed that DBCLT was significantly longer in the 34 overweight diabetic patients (437 +/- 68 min) than in the 69 diabetics at or below the ideal body weight (240 +/- 28 min) or in the 76 normalipidemic normal weight control subjects (253 +/- 12 min). DBCLT was also longer in the hypertrigliceridemic diabetic patients than in the normolipidemic ones. The mean lysis time was similar in diabetic patients with and without retinopathy. However, a higher level of fibrinolytic inhibitors was found in patients with diabetic small vessel disease. In vitro inhibition of plasma factor XIII by p-chlormercuribenzoate (PCMB) caused an acceleration of DBCLT and the differences between lysis time in the overweight diabetics and in the controls were attenuated. These results suggested that deficient thrombolysis is rather due to overweight and to disturbances of lipid metabolism than to diabets and/or its vascular complications and that enhanced fibrin crosslinking is at least partially responsible for delayed clot lysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6494764

Source DB:  PubMed          Journal:  Med Interne        ISSN: 0377-1202


  2 in total

1.  Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: towards a precision and personalized medicine approach.

Authors:  Etheresia Pretorius; Janette Bester
Journal:  Oncotarget       Date:  2016-08-09

2.  Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Douglas B Kell
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.